Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mirum Pharmaceuticals reports robust Q4 performance and growth strategies

Mirum Pharmaceuticals showcased strong financial performance and strategic growth initiatives in their Q4 2022 earnings call, driven by significant sales growth and positive study outcomes.
While the company faces challenges in maintaining market position and regulatory milestones, opportunities lie in upcoming milestones, product expansion, and market penetration strategies.
Overall, Mirum Pharmaceuticals' performance reflects a promising outlook for continued growth and innovation in the pharmaceutical sector, supported by a solid financial foundation and product pipeline.

Mirum Pharmaceuticals reports strong Q1 revenue and strategic growth plans

Mirum Pharmaceuticals' Q1 2023 earnings call showcased strong revenue performance, strategic initiatives, and promising pipeline milestones. The company's focus on LIVMARLI and expansion efforts position it well for future growth, despite facing regulatory and commercial challenges.

Mirum Pharmaceuticals reports robust Q2 performance and eyes strategic growth

Mirum Pharmaceuticals showcased strong financial performance, strategic progress, and a focus on innovation during the Q2 2023 earnings call.
The company's emphasis on pediatric hepatology, upcoming acquisitions, and commitment to bringing important medicines to patients globally position it for future success.
While facing challenges such as regulatory strategies and integration post-acquisition, Mirum has opportunities to drive growth through product expansion and market leadership.

Mirum Pharmaceuticals reports strong Q3 revenue and strategic acquisitions

Mirum Pharmaceuticals demonstrated solid performance in Q3 2023 with strong revenue and strategic acquisitions.
While facing challenges such as net losses and high operating expenses, the company maintains a strong financial position.
Opportunities lie in upcoming milestones, product commercialization, and financial optimization under new leadership.
Overall, Mirum Pharmaceuticals shows promise for growth and innovation in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q4 earnings and growth opportunities

Mirum Pharmaceuticals delivered strong financial results in Q4 2023, with significant revenue growth and net product sales.
Despite operating expenses and a net loss, the company remains well-funded and poised for growth in 2024.
Key milestones and progress in pipeline development highlight Mirum's commitment to innovation and market expansion.
Balancing financial performance with pipeline advancement and regulatory milestones will be crucial for Mirum's sustained success in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q1 sales growth and pipeline advancements

Mirum Pharmaceuticals demonstrated strong sales growth and financial stability in Q1 2024, driven by the success of LIVMARLI and advancements in product pipeline.
While facing challenges in managing expenses and navigating a competitive market, Mirum's focus on rare liver disease treatments presents significant opportunities for growth.
The company's commitment to innovation, gratitude for stakeholders, and strategic plans for NDA submissions underscore a promising outlook for future success.
Investors should monitor Mirum's progress in commercializing key products and expanding its market reach to capitalize on the growth potential in rare disease treatments.

Mirum Pharmaceuticals excels in Q2, eyes global expansion and innovation

Mirum Pharmaceuticals demonstrated impressive growth and achieved key milestones in Q2 2024, positioning the company for future success.
While facing challenges such as net losses and market competition, Mirum's strengths in product innovation and market expansion offer opportunities for sustained growth.
By focusing on cost management, regulatory compliance, and strategic partnerships, Mirum can navigate challenges and capitalize on opportunities to drive long-term value for stakeholders.

Mirum Pharmaceuticals excels in Q3, raises revenue guidance and expands pipeline

Mirum Pharmaceuticals delivered exceptional results in Q3 2024, showcasing strong financial performance, robust commercial programs, and promising pipeline advancements. With increased revenue guidance, breakthrough designations, and positive cash flow, the company is well-positioned for continued success. Challenges lie in maintaining growth momentum amidst competition and regulatory complexities, but opportunities for expansion and innovation abound.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Tim Walbert has been appointed to the company's Board of Directors. In addition to Mr. Walbert's appointment, the company shared that Niall O'Donnell, Ph.D., a Mirum director since November 2018, has announced his plan to step down from the Board of Directors concurrent with the upcoming 2023 Annual Meeting of Stockholders expected to be held on June 12, 2023.

Industry Leader Tim Walbert Joins Mirum Pharmaceuticals' Board of Directors

Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.

Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Corporate Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President and Chief Executive Officer Ian Clements - Chief Financial Officer Peter Radovich - Chief Operating Officer Pamela Vig - Head of R&D Conference Call Participants Jessica Fye - JPMorgan Mani Foroohar - SVB Securities Josh Schimmer - Evercore Ryan Deschner - Raymond James David Lebowitz - Citi Brian Skorney - Baird Ed Arce - H.C. Wainwright Yasmeen Rahimi - Piper Sandler Operator Good afternoon.

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Call Transcript

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Mirum Pharmaceuticals (MIRM) Might Surprise This Earnings Season

Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2022 financial results on Wednesday, March 8, 2023. Mirum will also host a conference call to discuss the fourth quarter and year-end 2022 financial results and recent corporate progress.

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has submitted a supplemental New Drug Application (sNDA) for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC).

Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the SVB Securities Global Biopharma Conference

Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference

Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 million in the U.S. alone.

Mirum Pharmaceuticals: In The Spotlight Following Buyout Of Albireo Pharma

FOSTER CITY, Calif.--( BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided a preview of the company's plans, estimated revenue and net product sales for Q4 and full year 2022 ahead of its presentation at the 41st Annual J.P. Morgan Healthcare Conference.

Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates

FOSTER CITY, Calif.--( BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023.

Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

FOSTER CITY, Calif.--( BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Lon Cardon, Ph.D., FMedSci, to its Board of Directors where he will also serve as a member of the Nominating and Governance Committee. Dr. Cardon brings nearly 30 years of extensive industry and academic experience in drug discovery and development.

Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors

FOSTER CITY, Calif.--( BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the European Commission has granted marketing authorization for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older. The approval follows a positive opinion granted by the European Committee for Medicinal Products for Human Use (CHMP) in September 2022. LIVMARLI is the first and only approved treatment in both the European Union and the United States to treat this rare liver disease affecting one out of 30,000 people globally.

Mirum Pharmaceuticals' LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older

FOSTER CITY, Calif.--( BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the decision to discontinue the OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to enrollment feasibility. ICP is a setting of cholestasis during pregnancy with pruritus and elevated bile acid levels that can lead to fetal complications. In an interim analysis, patients treated with volixibat saw meaningful reductions in serum bile acids and pruritus. However, due to the challenges in enrollment in this high-risk pregnancy setting, Mirum has decided to discontinue OHANA, which allows the company to prioritize other programs.

Mirum Pharmaceuticals Provides Development Program Updates

Mirum raised 2022 full year net product sales guidance estimate for LIVMARLI to $70 million. Potential to receive European approval of LIMVARLI for Alagille syndrome in patients aged 2 months and older. Decision expected before the end of 2022.

Mirum: Potential For European Approval To Move It Forward

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Ian Clements - CFO Chris Peetz - President, CEO & Director Peter Radovich - COO Pamela Vig - Head of R&D Richard Thompson - Professor, King's College London Conference Call Participants Jessica Fye - JPMorgan Steve Seedhouse - Raymond James Mani Foroohar - SVB Securities David Lebowitz - Citi Yasmeen Rahimi - Piper Sandler Thomas Yip - H.C. Wainwright Operator Hello, everyone, and welcome to the Mirum Q3 2022 Business Update.

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2022 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 2.86% and 11.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Misses Revenue Estimates

Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD

Mirum Pharmaceuticals, Inc. (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease

Positive Topline Data Announced from Mirum's LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)

Mirum Pharmaceuticals' LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics

News for Mirum Pharmaceuticals Inc Stock (MIRM)